ResMed Inc. (NYSE: RMD) is proving a popular choice among significant investors, with 74% of the company owned by institutional shareholders. Notably, the multinational corporation specializing in sleep-related and other respiratory medical equipment has delivered robust long-term gains, despite a temporary 4.5% dip in investor benefits last week. Various entities, including
Y Intercept Hong Kong Ltd, XTX Topco Ltd, and Franklin Resources Inc., have altered their positions in ResMed. Notably,
ResMed's stock rose 15% in Q3, and its first-quarter financial results for 2025 exceeded predictions. Long-term growth and a promising future for investors are among the primary reasons for its popularity. Firms such as
World Investment Advisors LLC and
Wellington Management Group LLP continue to acquire more shares, reflecting confidence in ResMed's strategic trajectory. Despite CFO Brett Sandercock and Director Peter Farrell selling some of their shares, the overall market sentiment remains positive. While there has been some concern over the CEO's compensation and some insider transactions, ResMed's solid financial performance, strong earnings growth, and brilliant execution offset these concerns, ensuring ResMed maintains a solid position on the radar of many investors.
Resmed RMD News Analytics from Fri, 26 Apr 2024 07:00:00 GMT to Fri, 20 Dec 2024 13:42:35 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor 2
